コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 fragment 8-37, an antagonist of one class of CGRP receptor.
2 ted peptide (h-alpha-CGRP) in activating the CGRP receptor.
3 in this position is not in contact with the CGRP receptor.
4 ed responses to alarmins in mice lacking the CGRP receptor.
5 are humanised antibodies against CGRP or the CGRP receptor.
6 plexes and was also conserved in the related CGRP receptor.
7 epant), an orally bioavailable antagonist of CGRP receptor.
8 ein-1 (hRAMP1), an obligatory subunit of the CGRP receptor.
9 cell surface as a mature glycoprotein and a CGRP receptor.
10 ly potent agonist effects of h-alpha-CGRP at CGRP receptors.
11 7) is preferred for high-affinity binding to CGRP receptors.
12 ubstantially increased binding affinities at CGRP receptors.
13 n of antagonists with increased affinity for CGRP receptors.
14 Phe caused no change in binding affinity at CGRP receptors.
15 of ADM receptors, but also to activation of CGRP receptors.
16 cluding the calcitonin gene-related peptide (CGRP) receptor.
17 1 to give a calcitonin gene-related peptide (CGRP) receptor.
18 nist of the calcitonin gene-related peptide (CGRP) receptor.
19 hat female-specific mechanisms downstream of CGRP receptor activation contribute to the higher preval
20 that RAMP1 is functionally rate limiting for CGRP receptor activity in the trigeminal ganglion, which
21 mucosal HIV-1 transmission and suggest that CGRP receptor agonists might be used therapeutically aga
22 we identified that molar pulp cells express CGRP receptor and Gli1, a Hedgehog (Hh) signaling protei
23 nstrated in whole muscle tissue, the type of CGRP receptor and its associated proteins or its cellula
24 n SK-N-MC and L6 cells expressing endogenous CGRP receptors and competed with labeled CGRP for bindin
25 Phe(37) of h-alpha-CGRP(8-37) for binding to CGRP receptors and have identified the N-terminus and Hi
26 e required for signal transduction at ocular CGRP receptors and is localized to sites previously repo
27 that mature and immature DCs express type 1 CGRP receptors and that signaling through these receptor
29 djacent to the lateral ventricle, is rich in CGRP receptors, and has itself been implicated in anxiet
38 responses, and systemic administration of a CGRP receptor antagonist similarly inhibited contact hyp
39 revealed the ability of this small molecule CGRP receptor antagonist to prevent activation and sensi
44 gepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that is approved for acute tre
45 l-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist under investigation for treatm
47 ll molecule calcitonin gene-related peptide (CGRP) receptor antagonist, was previously assessed in a
48 ll-molecule calcitonin gene-related peptide (CGRP) receptor antagonist-does not fully prevent activat
50 tide (CGRP), as treatment with the selective CGRP-receptor antagonist CGRP(8-37) prevented this effec
52 nce led to the development of small molecule CGRP receptor antagonists and monoclonal antibodies targ
57 ndent manner during CSD, and three different CGRP receptor antagonists had a dose-dependent inhibitor
60 ed by activation of interleukin 6 signaling, CGRP receptor antagonists olcegepant and CGRP(8-37) both
61 igger migraine in humans and the efficacy of CGRP receptor antagonists that evidently do no penetrate
62 ophysiology, have become available: gepants (CGRP receptor antagonists) and monoclonal antibodies dir
63 chemistry required to advance small molecule CGRP receptor antagonists, also called gepants, includin
65 investigated whether gepants, small molecule CGRP receptor antagonists, worsen cerebral ischemia.
71 rgeting the calcitonin gene-related peptide (CGRP) receptor approved for migraine prevention Although
72 t neurons in the central amygdala expressing CGRP receptors are also critical for establishing a thre
74 c phenotype was due to overexpression of the CGRP receptor at endogenous or novel expression sites.
77 essel vasculitis, potentially exacerbated by CGRP receptor blockade from erenumab, which may have imp
80 icin) and a calcitonin gene-related peptide (CGRP) receptor blocker (CGRP(8-37)) was also used to elu
81 PCR revealed expression of mRNA for a type 1 CGRP receptor by mature and immature blood-derived DCs.
82 opulation within the CeA of mice, defined by CGRP-receptor (Calcrl) expression, receives topographic
83 with lymphatic vasculature deficient in the CGRP receptor (CalcrliLEC mice) treated with nitroglycer
84 ical studies have shown that blockade of the CGRP receptor can produce antimigraine efficacy comparab
88 n myometrial contractions and the changes in CGRP receptors (CGRP-Rs) in human myometrium have not be
92 In situ hybridization demonstrated that the CGRP receptor component protein is expressed in outer ha
93 sensory nerve density was reduced and RAMP1 (CGRP receptor component) associated with nuclear regions
94 ously shown that this accessory protein, the CGRP-receptor component protein (RCP), is expressed in C
95 s, receptor activity modifying protein 1 and CGRP-receptor component protein, required for ligand spe
96 tion, and refolding of a soluble form of the CGRP receptor comprising a heterodimer of the CLR and RA
98 t that mice with normal levels of endogenous CGRP receptors demonstrate light avoidance following CGR
99 f sensory nerves or knockdown in vivo of the CGRP-receptor-encoding genes Calcrl or Ramp1 substantial
101 P gene, endothelium-specific inactivation of CGRP receptor gene, or treatment with CGRP receptor anta
102 itized mice that have elevated levels of the CGRP receptor hRAMP1 subunit in nervous tissue (nestin/h
104 We show that pharmacologic inactivation of CGRP receptors in old wild-type animals can restore meta
106 t and specific nonpeptide antagonists of the CGRP receptor, including olcegepant and telcagepant (K(D
107 ied ECD complex vs 233 pM for membrane-bound CGRP receptor), indicating that other regions of CLR and
108 results indicate that the activation of BNST CGRP receptors is both necessary and sufficient for some
109 evidence that the responsiveness of neuronal CGRP receptors is strongly enhanced in vitro and in vivo
110 we demonstrate that activation of endogenous CGRP receptors is sufficient to elicit light aversion in
112 ctional imaging study which investigated the CGRP receptor mAb (erenumab), we hypothesized that (i) t
115 We first demonstrated that activation of CGRP receptors on cultured trigeminal ganglion neurons i
116 on, we engineered a mouse lacking functional CGRP receptors on ECs (EC receptor activity modifying pr
117 ilic protein that is presumed to be either a CGRP receptor or a component of a CGRP receptor complex.
118 ke receptor (CRLR), can function as either a CGRP receptor or an adrenomedullin receptor, depending o
122 lencing of nociceptors and antagonism of the CGRP receptor RAMP1 all reduced the exhaustion of tumour
124 functional calcitonin gene-related peptide (CGRP) receptor requires dimerization of calcitonin recep
125 f small molecule antagonist affinity for the CGRP receptor reside within the extracellular region of
126 through the alpha(2)-adrenergic receptor and CGRP receptor, respectively, because blocking these rece
127 and small intestine, we assessed the role of CGRP receptor signaling during C rodentium infection.
128 t migraine inhibitors such as those blocking CGRP receptor signaling protect against acute IL-6 relea
132 th >100-fold higher affinities for the human CGRP receptor than for receptors from other species.
133 expression of RAMP1 and CRLR reconstituted a CGRP receptor that was able to activate the pheromone-si
137 trial of patients with CCH, blockade of the CGRP receptor with erenumab was not successful in the pr